Neurogen Corporation Announces R&D Update

BRANFORD, Conn.--(BUSINESS WIRE)--Neurogen Corporation (Nasdaq: NRGN) today updated the status of its later stage clinical portfolio and announced the future focus of its research efforts.
MORE ON THIS TOPIC